Drug Information

Drug General Information
Drug ID
D01CPZ
Former ID
DIB003603
Drug Name
ACP-196
Indication Chronic lymphocytic leukaemia [ICD10:C91] Phase 3 [525235]
Company
Acerta pharma
Structure
Download

3D MOL
Target and Pathway
Target(s) Tyrosine-protein kinase BTK Target Info Inhibitor [550507]
KEGG Pathway NF-kappa B signaling pathway
Osteoclast differentiation
Platelet activation
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Primary immunodeficiency
PANTHER Pathway B cell activation
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
FAS (CD95) signaling pathway
Class I PI3K signaling events
EPO signaling pathway
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome MyD88:Mal cascade initiated on plasma membrane
Regulation of actin dynamics for phagocytic cup formation
DAP12 signaling
FCERI mediated Ca+2 mobilization
MyD88 deficiency (TLR2/4)
IRAK4 deficiency (TLR2/4)
RHO GTPases Activate WASPs and WAVEs
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Kit receptor signaling pathway
MyD88:Mal cascade initiated on plasma membrane
Signaling by the B Cell Receptor (BCR)
DAP12 interactions
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
Regulation of toll-like receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 525235ClinicalTrials.gov (NCT02475681) Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL.
Ref 550507National Cancer Institute Drug Dictionary (drug id 756623).